Siegfried, a leading global CDMO for the pharmaceutical industry headquartered in Zofingen, has inaugurated its new global Research and Development center at its site in Evionnaz, located in the Valais canton. Siegfried specializes in manufacturing active pharmaceutical ingredients (APIs) and their intermediates, as well as drug products such as tablets, capsules, sterile vials, ampoules, cartridges, and ointments for the pharmaceutical industry.
The 4,500 square meter R&D center features advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies including flow chemistry, advanced distillation, and process analytical technology, along with new office spaces. In conjunction with the R&D center in Zofingen, this facility will provide chemical process R&D and analytical development services for Siegfried’s global network of Drug Substances. With workspaces for over 100 highly skilled professionals and the creation of 40 new jobs, the R&D center enhances Siegfried’s development capabilities.
Marcel Imwinkelried, CEO of Siegfried, stated: “The new R&D center in Evionnaz significantly strengthens our Drug Substances network and demonstrates our unwavering commitment to delivering cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our EVOLVE+ strategy and represents another pivotal step in solidifying our position among the top providers in the CDMO sector.”
Valais Canton, a strategic choice for Siegfried
Siegfried selected the canton of Valais for its new global R&D center due to its strategic importance within the company’s network and its long-standing presence in the region. Valais offers an ideal environment for the R&D center, boasting a strong reputation in the life sciences sector, a skilled workforce, and proximity to renowned research institutions. The location also benefits from excellent infrastructure and accessibility, facilitating efficient collaboration and exchange with Siegfried’s global partners and clients.
A Significant Milestone in Siegfried’s Growth Strategy
In 2023, the company reported sales of CHF 1.272 billion and employed over 3,700 people across eleven sites on three continents. As explained at the project launch in April 2023, the new R&D center in Evionnaz plays a key role for the company’s global network and its commitment to providing advanced research and development services to customers. The center represents a significant milestone in Siegfried’s growth strategy and an important step toward becoming a leader in the CDMO space.
Source: Siegfried press release
Copyright photos: Siegfried